BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

CogState Ltd (CGS.AX) Signs Licensing Deal With Merck Canada


6/25/2012 7:25:11 AM

June 25, 2012 -- CogState (ASX:CGS) has signed a deal giving Merck Canada the exclusive right to market its cognition measurement tests to Canadian doctors.

The companies expect the first commercial sale under the partnership to close before the end of the year.

This marks the first of what is likely to be a series of commercial arrangements to provide CogState's battery of tests to general practitioners.

The commercial terms of the deal were not disclosed, but CogState CEO Brad O'Connor said the agreement “represents the first stage of commercialising the CogState Test in general practice medicine.”

CogState plans to position its tests as tools to help detect the early onset of neurodegenerative conditions including Alzheimer's disease.

O'Connor said Canada was an important target region for the tests, and Merck Canada was the right partner to help break into the market.

CogState tests are currently used in clinical trials and research projects, as well as for sports concussion management and cognitive state testing in the workplace.

CogState the company was founded in 1999 and listed on the ASX in 2004.

In February, the company revealed it had swung to a 1H net profit of $3.4 million, from a $895,000 loss a year earlier.

CogState (ASX:CGS) shares got a 20% bump on the back of the announcement, trading at $0.300 as of around 2:30pm on Monday.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES